Natera, Inc. (NASDAQ:NTRA) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRAFree Report) by 257.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 307,716 shares of the medical research company’s stock after buying an additional 221,517 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.25% of Natera worth $28,144,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. YHB Investment Advisors Inc. acquired a new stake in shares of Natera in the first quarter worth $36,000. RiverPark Advisors LLC acquired a new stake in Natera during the fourth quarter worth about $27,000. Principal Securities Inc. purchased a new position in Natera during the fourth quarter valued at approximately $32,000. Arcadia Investment Management Corp MI lifted its holdings in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 174 shares during the period. Finally, Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Up 1.0 %

Shares of NTRA stock opened at $112.74 on Friday. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $117.23. The company’s 50-day moving average price is $106.53 and its 200-day moving average price is $87.63. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRAGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.16. The business had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business’s revenue for the quarter was up 52.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.23) EPS. As a group, equities analysts expect that Natera, Inc. will post -2.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NTRA shares. The Goldman Sachs Group increased their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Canaccord Genuity Group increased their price target on Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research report on Friday, April 5th. TD Cowen increased their target price on Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Finally, BTIG Research lifted their target price on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, May 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $101.19.

Get Our Latest Report on NTRA

Insider Buying and Selling at Natera

In other news, CFO Michael Burkes Brophy sold 4,983 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.37, for a total transaction of $540,007.71. Following the completion of the transaction, the chief financial officer now directly owns 75,059 shares in the company, valued at approximately $8,134,143.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Steven Leonard Chapman sold 6,105 shares of Natera stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $111.61, for a total value of $681,379.05. Following the completion of the sale, the chief executive officer now owns 213,351 shares in the company, valued at approximately $23,812,105.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 4,983 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.37, for a total value of $540,007.71. Following the transaction, the chief financial officer now owns 75,059 shares in the company, valued at $8,134,143.83. The disclosure for this sale can be found here. Insiders have sold 201,770 shares of company stock worth $20,023,161 over the last quarter. 7.60% of the stock is currently owned by company insiders.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.